Dedicated to Early Disease Detection and Prevention
Founded in the third quarter of 2014, Bio Preventive Medicine (BPM) is a biotech R&D and diagnostic service company centered on novel biomarker technologies. We are dedicated to the development of high value-added products for early disease detection and prevention.
The name "Bio Preventive Medicine" embodies our core vision: to fulfill the ultimate goal of preventive medicine through innovative biomarker diagnostics. Our strategic focus is on developing products for high-incidence diseases globally, leveraging a strong niche and foundation in the Asia-Pacific region.
Leveraging Biomarker Technologies to
Drive Two Major Business Opportunities
Developing high value-added diagnostic products for early disease screening and prevention.
Forming strategic alliances with leading global pharmaceutical companies to share in the lucrative opportunities of new drug development.
Precision from Bench to Bedside
Bio Preventive Medicine (BPM) is dedicated to the "last mile" of Translational Medicine. Grounded in rigorous scientific evidence, we transform innovative biomarkers into reliable diagnostic tools, realizing the true promise of precision medicine.
Discovery
Utilizing advanced proteomics to identify novel biomarkers with significant clinical relevance.
Clinical Validation
Executing multinational, multicenter trials and real-world data (RWD) analysis to establish robust clinical utility.
Commericialization
Integrating global patent strategies, driving inclusion in international clinical guidelines, and securing health insurance reimbursement to launch products worldwide.
Analytical Validation
Developing high-quality, highly reproducible diagnostic assays in compliance with international laboratory standards, such as CLSI.
Regulator Approval
Strategizing optimal regulatory pathways to secure market authorizations, including EU IVDR, Taiwan TFDA, and approvals in multiple countries.
Global Dual-Track Strategy
Driven by our proprietary, patented biomarker platform, Bio Preventive Medicine (BPM) employs an agile, dual-engine business strategy. We simultaneously cultivate end-markets through strategic Channel Distribution, while expanding our global footprint via Technology Licensing, ultimately maximizing the commercial value of our core technologies.
Channel Distribution
Building a global sales network centered on our innovative, GMP-compliant In Vitro Diagnostic (IVD) products and Laboratory Developed Test (LDT) kits.
Proven Track Record
Strategically deployed in 42+ countries globally, covering markets across the EU, Southeast Asia, and the Middle East.
Multi-Tiered Market Penetration
Covering large-to-medium medical institutions, primary care clinics, medical groups, and multi-center clinical validations.
Global Expansion
Collaborating with clinical research institutions and laboratories, and joining forces with strategic partners and KOLs to execute marketing trials, accelerating global commercialization.
Technology Licensing
Leveraging comprehensive patent protection and control over key raw materials, we utilize technology licensing to transcend platform limitations and maximize market penetration.
Success Case
Successfully licensed to major Korean manufacturer, Boditech Med Inc., for integration into Point-of-Care Testing (POCT) products.
Cross-Platform Application
Targeting the market opportunity of 500 million diabetic patients worldwide by integrating biomarkers into diverse testing platforms, including POCT.
Sustainable Revenue Streams
Projected to generate stable royalty income while continuously expanding strategic alliances with major international players.
Corporate Headquarters
Located in the Tai Yuen Hi-Tech Industrial Park in Zhubei, our headquarters houses a state-of-the-art testing laboratory and a diagnostic reagent manufacturing facility. Both are internationally ISO 13485 certified and operate in strict compliance with Taiwan FDA GMP and EU BSI IVDR/QMS standards.
